Skip to main content

Eruptive Melanocytic Nevi: A Review

Abstract

Eruptive melanocytic nevi (EMN) is a phenomenon characterized by the sudden onset of nevi. Our objective was to compile all published reports of EMN to identify possible precipitating factors and to evaluate the clinical appearance and course. We conducted a systematic bibliographic search and selected 93 articles, representing 179 patients with EMN. The suspected causes were skin and other diseases (50%); immunosuppressive agents, chemotherapy or melanotan (41%); and miscellaneous, including idiopathic (9%). The clinical manifestations could largely be divided into two categories: EMN associated with skin diseases were frequently few in number (fewer than ten nevi), large, and localized to the site of previous skin disease, whereas those due to other causes presented most often with multiple small widespread nevi. In general, EMN seem to persist unchanged after their appearance, but development over several years or fading has also been reported. Overall, 16% of the cases had at least one histologically confirmed dysplastic nevus. Five cases of associated melanoma were reported. We conclude that the clinical appearance of EMN may differ according to the suggested triggering factor. Based on the clinical distinction, we propose a new subclassification of EMN: (1) widespread eruptive nevi (WEN), with numerous small nevi, triggered by, for example, drugs and internal diseases, and (2) Köbner-like eruptive nevi, often with big and few nevi, associated with skin diseases and most often localized at the site of previous skin disease/trauma. The nature of the data precluded assessment of risk of malignant transformation.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

Notes

  1. 21 cases of EMN after exposure to sulfur gas were excluded because of selection bias; all cases were male soldiers.

  2. ABCDE: asymmetry, border irregularity, color that is not uniform, diameter > 6 mm, evolving size, shape or color.

  3. Days includes ≤ 14 days and “a few days” and “several days”. Weeks includes > 14 days to ≤ 8 weeks and “a few weeks” and “several weeks”. A few months includes > 8 weeks to ≤ 4 months and “a few months”. Several months includes > 4 months to ≤ 1 year and “several months”. “Years” includes > 1 year.

  4. References include unpublished data obtained via correspondence with authors.

References

  1. Hutchinson J. Outbreak of a large crop of moles. Remarks as to possible connection with melanosis. J Cutan Med Dis Skin. 1868:170–171.

  2. Coskey RJ. Letter: eruptive nevi. Arch Dermatol. 1975;111(12):1658.

    CAS  PubMed  Google Scholar 

  3. John JK, Smalley KS. Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis? Expert Rev Anticancer Ther. 2011;11(5):711–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Salopek TG, Mahmood MN. Eruptive melanocytic nevi induced by interferon for nodal metastatic melanoma: case report and review of the literature. J Cutan Med Surg. 2013;17(6):410–3.

    PubMed  Google Scholar 

  5. Sekulic A, Colgan MB, Davis MD, et al. Activating BRAF mutations in eruptive melanocytic naevi. Br J Dermatol. 2010;163(5):1095–8.

    CAS  PubMed  Google Scholar 

  6. Gelfer A, Rivers JK. Long-term follow-up of a patient with eruptive melanocytic nevi after Stevens-Johnson syndrome. Arch Dermatol. 2007;143(12):1555–7.

    PubMed  Google Scholar 

  7. Banky JP, Kelly JW, English DR, et al. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol. 2005;141(8):998–1006.

    PubMed  Google Scholar 

  8. Siskind V, Darlington S, Green L, et al. Evolution of melanocytic nevi on the faces and necks of adolescents: a 4 y longitudinal study. J Invest Dermatol. 2002;118(3):500–4.

    CAS  PubMed  Google Scholar 

  9. MacKie RM, English J, Aitchison TC, et al. The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol. 1985;113(2):167–74.

    CAS  PubMed  Google Scholar 

  10. Belloni Fortina A, Piaserico S, Zattra E, et al. Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn’s disease. Melanoma Res. 2005;15(3):223–4.

    PubMed  Google Scholar 

  11. Wonders J, De Boer NK, Van Weyenberg SJ. Spot diagnosis: eruptive melanocytic naevi during azathioprine therapy in Crohn’s disease. J Crohns Colitis. 2012;6(5):636.

    PubMed  Google Scholar 

  12. Woodhouse J, Maytin EV. Eruptive nevi of the palms and soles. J Am Acad Dermatol. 2005;52(5 Suppl 1):S96–100.

    PubMed  Google Scholar 

  13. Kakrida M, Orengo I, Markus R. Sudden onset of Multiple nevi after administration of 6-mercaptopurine in an adult with Crohn’s disease: a case report. Int J Dermatol. 2005;44(4):334–6.

    PubMed  Google Scholar 

  14. Lopez V, Molina I, Martin JM, et al. Eruptive nevi in a patient receiving cyclosporine A for psoriasis treatment. Arch Dermatol. 2010;146(7):802–4.

    PubMed  Google Scholar 

  15. de Boer NK, Kuyvenhoven JP. Eruptive benign melanocytic naevi during immunosuppressive therapy in a Crohn’s disease patient. Inflamm Bowel Dis. 2011;17(6):E26.

    PubMed  Google Scholar 

  16. Uhlenhake EE, Watson AC, Aronson P. Sorafenib induced eruptive melanocytic lesions. Dermatol Online J. 2013;19(5):18184.

    PubMed  Google Scholar 

  17. Jimenez-Gallo D, Albarran-Planelles C, Linares-Barrios M, et al. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib. JAMA Dermatol. 2013;149(5):624–6.

    PubMed  Google Scholar 

  18. Villalon G, Martin JM, Pinazo MI, et al. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine. Am J Clin Dermatol. 2009;10(4):261–3.

    PubMed  Google Scholar 

  19. Alaibac M, Piaserico S, Rossi CR, et al. Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings. J Am Acad Dermatol. 2003;49(6):1020–2.

    PubMed  Google Scholar 

  20. Bovenschen HJ, Tjioe M, Vermaat H, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol. 2006;154(5):880–4.

    CAS  PubMed  Google Scholar 

  21. Melo JN, Teruya PY, Machado MC, et al. Epidermolysis bullosa nevi: clinical, dermatoscopical and histological features in a case of recessive dystrofic form. An Bras Dermatol. 2011;86(4):743–6.

    PubMed  Google Scholar 

  22. Ratushny V, Kraft S, Moschella SL, et al. A symmetric eczematous eruption harboring thousands of melanocytic lesions. JAMA Dermatol. 2016;152(9):1021–4.

    PubMed  Google Scholar 

  23. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):34–6.

    CAS  PubMed  Google Scholar 

  24. Paurobally D, Jason F, Dezfoulian B, et al. Melanotan-associated melanoma. Br J Dermatol. 2011;164(6):1403–5.

    CAS  PubMed  Google Scholar 

  25. Donati, P., G. Paolino, M. Donati, et al., Cutaneous mastocytosis combined with eruptive melanocytic nevi and melanoma. Coincidence or a linkage in the pathogenesis? J Dermatol Case Rep. 2014;8(3):70–4.

  26. Munguia-Calzada P, Vivanco B, Oliva-Nacarino P, et al. Melanoma, eruptive naevi and natalizumab: causal relation or coincidence? Australas J Dermatol. 2017;58(4):330–1.

    PubMed  Google Scholar 

  27. Reutter JC, Long EM, Morrell DS, et al. Eruptive post-chemotherapy in situ melanomas and dysplastic nevi. Pediatr Dermatol. 2007;24(2):135–7.

    PubMed  Google Scholar 

  28. Bogenrieder T, Weitzel C, Scholmerich J, et al. Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma? Dermatology. 2002;205(2):174–5.

    PubMed  Google Scholar 

  29. Schmitt L, Schumann T, Inhoff O, et al. Eruptive nevi mimicking wart-like lesions under selective BRAF inhibition in a 37-year-old female melanoma patient. Case Rep Dermatol. 2013;5(1):69–72.

    PubMed  PubMed Central  Google Scholar 

  30. Arnold SJ, Bowling J. Eruptive acral naevi following chemotherapy for acute lymphoblastic leukaemia follow typical acral dermoscopic patterns. Australas J Dermatol. 2013;54(2):126–8.

    PubMed  Google Scholar 

  31. Ma L, Dominguez AR, Collins GR, et al. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib. Arch Dermatol. 2012;148(12):1428–9.

    PubMed  Google Scholar 

  32. Zalaudek I, Moscarella E, Sturm RA, et al. ‘Eruptive’ amelanotic compound nevi in children with facial freckles and pale skin colour: more than an occasion? J Eur Acad Dermatol Venereol. 2013;27(12):1583–5.

    CAS  PubMed  Google Scholar 

  33. Sibaud V, Munsch C, Lamant L. Eruptive nevi and hair depigmentation related to regorafenib. Eur J Dermatol. 2015;25(1):85–6.

    PubMed  Google Scholar 

  34. Duvic M, Lowe L, Rapini RP, et al. Eruptive dysplastic nevi associated with human immunodeficiency virus infection. Arch Dermatol. 1989;125(3):397–401.

    CAS  PubMed  Google Scholar 

  35. Piaserico S, Alaibac M, Fortina AB, et al. Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. J Am Acad Dermatol. 2006;54(2):338–40.

    PubMed  Google Scholar 

  36. Kim M, Yoon YH, Lee JH, et al. Eruptive melanocytic naevi caused by radotinib therapy in patients with chronic myeloid leukaemia: 10 cases and a literature review. Acta Derm Venereol. 2017;97(1):115–6.

    CAS  PubMed  Google Scholar 

  37. Burian, E. and E. Burian, [Eruptive nevi after injection of drugs marketed as melanotan II. The first two Swedish cases described]. Lakartidningen. 2013;110(5):208–10.

  38. Thestrup-Pedersen K, Sondergaard K. Melanotan-induced lentigines and nevi. Ugeskr Laeger. 2011;173(13):975.

    PubMed  Google Scholar 

  39. Cardones AR, Grichnik JM. alpha-Melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol. 2009;145(4):441–4.

    PubMed  Google Scholar 

  40. Lebeau S, Braun RP, Masouye I, et al. Acquired melanocytic naevus in childhood vulval pemphigoid. Dermatology. 2006;213(2):159–62.

    CAS  PubMed  Google Scholar 

  41. Cash SH, Dever TT, Hyde P, et al. Epidermolysis bullosa nevus: an exception to the clinical and dermoscopic criteria for melanoma. Arch Dermatol. 2007;143(9):1164–7.

    PubMed  Google Scholar 

  42. Koga M, Koga K, Imafuku S. Spontaneous regression of an epidermolysis bullosa nevus on the sole. J Dermatol. 2015;42(1):37–9.

    PubMed  Google Scholar 

  43. Lee JH, Kang JH, Cho BK, et al. Dysplastic nevus with eruptive melanocytic lesions that developed during nilotinib therapy for chronic myeloid leukemia. Ann Dermatol. 2015;27(6):782–4.

    PubMed  PubMed Central  Google Scholar 

  44. Kopf AW, Grupper C, Baer RL, et al. Eruptive nevocytic nevi after severe bullous disease. Arch Dermatol. 1977;113(8):1080–4.

    CAS  PubMed  Google Scholar 

  45. Shoji T, Cockerell CJ, Koff AB, et al. Eruptive melanocytic nevi after Stevens-Johnson syndrome. J Am Acad Dermatol. 1997;37(2 Pt 2):337–9.

    CAS  PubMed  Google Scholar 

  46. Goerz G, Tsambaos D. Eruptive nevocytic nevi after Lyell’s syndrome. Arch Dermatol. 1978;114(9):1400–1.

    CAS  PubMed  Google Scholar 

  47. Lanschuetzer CM, Emberger M, Hametner R, et al. Pathogenic mechanisms in epidermolysis bullosa naevi. Acta Derm Venereol. 2003;83(5):332–7.

    CAS  PubMed  Google Scholar 

  48. Lanschuetzer CM, Klausegger A, Pohla-Gubo G, et al. A novel homozygous nonsense deletion/insertion mutation in the keratin 14 gene (Y248X; 744delC/insAG) causes recessive epidermolysis bullosa simplex type Kobner. Clin Exp Dermatol. 2003;28(1):77–9.

    CAS  PubMed  Google Scholar 

  49. Gallardo F, Toll A, Malvehy J, et al. Large atypical melanocytic nevi in recessive dystrophic epidermolysis bullosa: clinicopathological, ultrastructural, and dermoscopic study. Pediatr Dermatol. 2005;22(4):338–43.

    PubMed  Google Scholar 

  50. Kirby JD, Darley CR. Eruptive melanocytic naevi following severe bullous disease. Br J Dermatol. 1978;99(5):575–80.

    CAS  PubMed  Google Scholar 

  51. Erfan N, Cardot-Leccia N, Sirvent A, et al. Eruptive nevi following bone marrow transplantation: a reflectance confocal microscopy study. J Eur Acad Dermatol Venereol. 2012;26(8):1043–4.

    CAS  PubMed  Google Scholar 

  52. McCourt C, Feighery C, McIntyre G, et al. Eruptive nevi in prostate cancer: is this a paraneoplastic phenomenon? Int J Dermatol. 2013;52(2):212–3.

    PubMed  Google Scholar 

  53. Lattouf C, Schachner L. Epidermolysis bullosa simplex, Dowling-Meara type with eruptive nevi. Int J Dermatol. 2012;51(9):1094–6.

    PubMed  Google Scholar 

  54. Stavrianeas NG, Katoulis AC, Moussatou V, et al. Eruptive large melanocytic nevus in a patient with hereditary epidermolysis bullosa simplex. Dermatology. 2003;207(4):402–4.

    CAS  PubMed  Google Scholar 

  55. Bong HW, Lee SJ, Lee KH, et al. Disseminated eruptive nevocellular nevi. J Dermatol. 1995;22(4):292–7.

    CAS  PubMed  Google Scholar 

  56. Natsuga K, Akiyama M, Sato-Matsumura KC, et al. Two cases of atypical melanocytic lesions in recessive dystrophic epidermolysis bullosa infants. Clin Exp Dermatol. 2005;30(6):636–9.

    CAS  PubMed  Google Scholar 

  57. Dictionary.com. http://www.dictionary.com/browse/eruptive. [cited 2018 07 April].

  58. Perry BM, Nguyen A, Desmond BL, et al. Eruptive nevi associated with medications (ENAMs). J Am Acad Dermatol. 2016;75(5):1045–52.

    PubMed  Google Scholar 

  59. Hughes BR, Cunliffe WJ, Bailey CC. Excess benign melanocytic naevi after chemotherapy for malignancy in childhood. BMJ. 1989;299(6691):88–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Baird EA, McHenry PM, MacKie RM. Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi. BMJ. 1992;305(6857):799–801.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Andreani V, Richard MA, Blaise D, et al. Naevi in allogeneic bone marrow transplantation recipients: the effect of graft-versus-host disease on naevi. Br J Dermatol. 2002;147(3):433–41.

    CAS  PubMed  Google Scholar 

  62. Smith CH, McGregor JM, Barker JN, et al. Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol. 1993;28(1):51–5.

    CAS  PubMed  Google Scholar 

  63. Grob JJ, Bastuji-Garin S, Vaillant L, et al. Excess of nevi related to immunodeficiency: a study in HIV-infected patients and renal transplant recipients. J Invest Dermatol. 1996;107(5):694–7.

    CAS  PubMed  Google Scholar 

  64. Szepietowski J, Wasik F, Szepietowski T, et al. Excess benign melanocytic naevi in renal transplant recipients. Dermatology. 1997;194(1):17–9.

    CAS  PubMed  Google Scholar 

  65. Koseoglu G, Akay BN, Kucuksahin O, et al. Dermoscopic changes in melanocytic nevi in patients receiving immunosuppressive and biologic treatments: results of a prospective case-control study. J Am Acad Dermatol. 2015;73(4):623–9.

    PubMed  Google Scholar 

  66. Naldi L, Adamoli L, Fraschini D, et al. Number and distribution of melanocytic nevi in individuals with a history of childhood leukemia. Cancer. 1996;77(7):1402–8.

    CAS  PubMed  Google Scholar 

  67. Crincoli E, Moliterni E, Catania F, et al. Correlation of serum tryptase levels with total number of nevi, Breslow thickness, ulceration, and mitotic index in melanoma patients: evaluation of a promising prognostic marker. Melanoma Res. 2018;. https://doi.org/10.1097/CMR.0000000000000561.

    Article  Google Scholar 

  68. Evans-Brown M, Dawson RT, Chandler M, et al. Use of melanotan I and II in the general population. BMJ. 2009;338:b566.

    PubMed  Google Scholar 

  69. Ross AL, Sanchez MI, Grichnik JM. Nevogenesis: a benign metastatic process? ISRN Dermatol. 2011;2011:813513.

    PubMed  PubMed Central  Google Scholar 

  70. Lee, G., M.C. Massa, S. Welykyj, et al., Yield from total skin examination and effectiveness of skin cancer awareness program. Findings in 874 new dermatology patients. Cancer. 1991;67(1):202–5.

    CAS  PubMed  Google Scholar 

  71. Crutcher WA, Sagebiel RW. Prevalence of dysplastic naevi in a community practice. Lancet. 1984;1(8379):729.

    CAS  PubMed  Google Scholar 

  72. Augustsson A, Stierner U, Suurkula M, et al. Prevalence of common and dysplastic naevi in a Swedish population. Br J Dermatol. 1991;124(2):152–6.

    CAS  PubMed  Google Scholar 

  73. Nordlund JJ, Kirkwood J, Forget BM, et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res. 1985;45(4):1855–61.

    CAS  PubMed  Google Scholar 

  74. Karlsson P, Stenberg B, Rosdahl I. Prevalence of pigmented naevi in a Swedish population living close to the Arctic Circle. Acta Derm Venereol. 2000;80(5):335–9.

    CAS  PubMed  Google Scholar 

  75. Holly EA, Kelly JW, Shpall SN, et al. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol. 1987;17(3):459–68.

    CAS  PubMed  Google Scholar 

  76. Roush GC, Nordlund JJ, Forget B, et al. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med. 1988;17(3):273–9.

    CAS  PubMed  Google Scholar 

  77. Goldstein AM, Tucker MA. Dysplastic nevi and melanoma. Cancer Epidemiol Biomark Prev. 2013;22(4):528–32.

    Google Scholar 

  78. Grulich AE, Bataille V, Swerdlow AJ, et al. Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. Int J Cancer. 1996;67(4):485–91.

    CAS  PubMed  Google Scholar 

  79. Moon IJ, Won CH, Lee MW, et al. Eruptive benign melanocytic nevi formation following adalimumab therapy in a patient with Crohn’s disease. Ann Dermatol. 2016;28(6):777–9.

    PubMed  PubMed Central  Google Scholar 

  80. Mansour Y, Lambert A, Tebacher-Alt M, et al. Eruptive nevi under tocilizumab: first case report and data analysis. J Eur Acad Dermatol Venereol. 2018;32(6):e253–4.

    CAS  PubMed  Google Scholar 

  81. Prabhu AV, Bibee K, English JC. Eruptive melanocytic acral nevi in the setting of 6-mercaptopurine therapy. J Drugs Dermatol. 2017;16(5):516–8.

    PubMed  Google Scholar 

  82. Kravvas G, Kavanagh GM. Eruptive melanocytic naevi secondary to azathioprine: case report and review of the literature. Clin Exp Dermatol. 2018;43(1):106–7.

    CAS  PubMed  Google Scholar 

  83. Steinweg SA, Halvorson CR, Kao GF, et al. Eruptive melanocytic nevi during azathioprine therapy for antisynthetase syndrome. Cutis. 2017;99(4):268–70.

    PubMed  Google Scholar 

  84. Barker JN, MacDonald DM. Eruptive dysplastic naevi following renal transplantation. Clin Exp Dermatol. 1988;13(2):123–5.

    CAS  PubMed  Google Scholar 

  85. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691–7.

    CAS  PubMed  Google Scholar 

  86. Chen FW, Tseng D, Reddy S, et al. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatol. 2014;150(11):1209–12.

    PubMed  Google Scholar 

  87. Kong, H.H., V. Sibaud, M.L. Chanco Turner, et al., Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144(6):820–2.

  88. Santiago F, Goncalo M, Reis JP, et al. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients. An Bras Dermatol. 2011;86(3):483–90.

    PubMed  Google Scholar 

  89. Anforth RM, Carlos GR, Scolyer RA, et al. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. Melanoma Res. 2015;25(1):91–4.

    PubMed  Google Scholar 

  90. Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67(6):1265–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Calleja-Algarra A, Aragon-Miguel R, Velasco-Tamariz V, et al. Eruptive nevi in a patient with metastatic breast cancer. Int J Dermatol. 2017;56(12):1508–9.

    PubMed  Google Scholar 

  92. Hughes B, Bailey CC. Excess benign melanocytic naevi. BMJ. 1989;299(6703):854–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Dertlioglu SB, Bitiren M, Cicek D. A case with postchemotherapy eruptive compound nevus. Indian J Dermatol. 2011;56(6):737–9.

    PubMed  PubMed Central  Google Scholar 

  94. Schulze F, Erdmann H, Hardkop LH, et al. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. Eur J Dermatol. 2014;24(1):107–9.

    PubMed  Google Scholar 

  95. Cousen P, Colver G, Helbling I. Eruptive melanocytic naevi following melanotan injection. Br J Dermatol. 2009;161(3):707–8.

    CAS  PubMed  Google Scholar 

  96. Hueso-Gabriel L, Mahiques Santos L, Terradez Mas L, et al. [Eruptive dysplastic nevi following melanotan use]. Actas Dermosifiliogr. 2012;103(4):329–31.

    CAS  Google Scholar 

  97. Reid C, Fitzgerald T, Fabre A, et al. Atypical melanocytic naevi following melanotan injection. Ir Med J. 2013;106(5):148–9.

    CAS  PubMed  Google Scholar 

  98. Bauer JW, Schaeppi H, Kaserer C, et al. Large melanocytic nevi in hereditary epidermolysis bullosa. J Am Acad Dermatol. 2001;44(4):577–84.

    CAS  PubMed  Google Scholar 

  99. Cotrim CP, Simone FT, Lima RB, et al. Epidermolysis bullosa nevus: case report and literature review. An Bras Dermatol. 2011;86(4):767–71.

    PubMed  Google Scholar 

  100. Fernandes JD, Rivitti-Machado MC, Nakano J et al. Clinical, dermoscopic and histopathological features of melanocytic nevi in dystrophic epidermolysis bullosa. J Dtsch Dermatol Ges. 2014;12(3):237–42, 237–43.

    PubMed  Google Scholar 

  101. Sugiyama-Fukamatsu H, Suzuki N, Nakanishi G, et al. Epidermolysis bullosa nevus arising in a patient with Dowling-Meara type epidermolysis bullosa simplex with a novel K5 mutation. J Dermatol. 2009;36(8):447–52.

    CAS  PubMed  Google Scholar 

  102. de Queiroz Fuscaldi LA, Bucard AM, Alvarez CD et al. Epidermolysis bullosa nevi: report of a case and review of the literature. Case Rep Dermatol. 2011;3(3):235–9.

    Google Scholar 

  103. Collantes-Rodriguez C, Jimenez-Gallo D, Arjona-Aguilera C, et al. Eruptive melanocytic nevi in a patient with toxic epidermal necrolysis-like cutaneous lupus. Lupus. 2018:961203317751064.

  104. Firooz A, Komeili A, Dowlati Y. Eruptive melanocytic nevi and cherry angiomas secondary to exposure to sulfur mustard gas. J Am Acad Dermatol. 1999;40(4):646–7.

    CAS  PubMed  Google Scholar 

  105. Soltani K, Bernstein JE, Lorincz AL. Eruptive nevocytic nevi following erythema multiforme. J Am Acad Dermatol. 1979;1(6):503–5.

    CAS  PubMed  Google Scholar 

  106. Mollet T, Henderson FW, Groben PA, et al. Epidermolysis bullosa nevus-like lesions in a pediatric patient with pyoderma gangrenosum. Pediatr Dermatol. 2011;28(1):32–4.

    PubMed  Google Scholar 

  107. Katoulis AC, Sgouros D, Argenziano G, et al. Surgical suturing-induced melanocytic nevi. A new type of eruptive melanocytic nevi? J Dermatol Case Rep. 2016;10(3):49–52.

  108. Navarini AA, Kolm I, Calvo X, et al. Trauma as triggering factor for development of melanocytic nevi. Dermatology. 2010;220(4):291–6.

    PubMed  Google Scholar 

  109. Tareen A, Pallesen K, Vestergaard T. Eruptive nevi after burn injury. Dermatol Pract Concept. 2018;8(1):66–7.

    PubMed  PubMed Central  Google Scholar 

  110. Betlloch I, Amador C, Chiner E, et al. Eruptive melanocytic nevi in human immunodeficiency virus infection. Int J Dermatol. 1991;30(4):303.

    CAS  PubMed  Google Scholar 

  111. Ibsen HH, Clemmensen O. Eruptive nevi in Addison’s disease. Arch Dermatol. 1990;126(9):1239–40.

    CAS  PubMed  Google Scholar 

  112. Koelemij I, Massolt ET, van Doorn R. Eruptive melanocytic naevi as a sign of primary adrenocortical insufficiency. Clin Exp Dermatol. 2013;38(8):927–9.

    CAS  PubMed  Google Scholar 

  113. Surinach C, Bahadoran P, Vabres P, et al. Flexural agminated eruptive nevi in Langerhans cell histiocytosis. JAMA Dermatol. 2013;149(5):635–7.

    PubMed  Google Scholar 

  114. Richert S, Bloom EJ, Flynn K, et al. Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukemia: case report and review of the literature. J Am Acad Dermatol. 1996;35(2 Pt 2):326–9.

    CAS  PubMed  Google Scholar 

  115. Kibbi N, Ariyan S, Slogoff F, et al. Eruptive melanocytic nevi heralding the diagnosis of metastatic malignant melanoma: a case report. JAAD Case Rep. 2015;1(2):74–6.

    PubMed  PubMed Central  Google Scholar 

  116. Kim DH, Lee JS, Koo DW, et al. Eruptive melanocytic nevi with satellite lesions following insulin treatment in a girl with type 1 diabetes mellitus. J Dermatol. 2015;42(5):547–8.

    PubMed  Google Scholar 

  117. Eady RA, Gilkes JJ, Jones EW. Eruptive naevi: report of two cases, with enzyme histochemical, light and electron microscopical findings. Br J Dermatol. 1977;97(3):267–78.

    CAS  PubMed  Google Scholar 

  118. J H. Outbreak of a large crop of moles. Remarks as to possible connection with melanosis. J Cutan Med Dis Skin. 1868;170–1.

  119. Lee WK, Jin H, You HS, et al. Eruptive melanocytic nevi without any trigger in a 5-year-old healthy girl. Ann Dermatol. 2017;29(5):644–6.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ewa A. Burian.

Ethics declarations

Funding

No sources of funding were used to conduct this review or prepare this manuscript.

Conflicts of interest

EB and GJ have no conflicts of interest that are directly relevant to the content of this article.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Burian, E.A., Jemec, G.B.E. Eruptive Melanocytic Nevi: A Review. Am J Clin Dermatol 20, 669–682 (2019). https://doi.org/10.1007/s40257-019-00444-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-019-00444-8